Clinical Research Papers:
An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
Metrics: PDF 897 views | HTML 1480 views | ?
Ling Li1,*, Sa Xiao1,*, Lei Zhang1, Xin Li1, Xiaorui Fu1, Xinhua Wang1, Jingjing Wu1, Zhenchang Sun1, Xudong Zhang1, Yu Chang1, Feifei Nan1, Jiaqin Yan1, Zhaoming Li1, Mengyuan Shi2, Ken H. Young3 and Mingzhi Zhang1
1Department of Oncology, Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
*These authors contributed equally to this work
Mingzhi Zhang, email: email@example.com
Keywords: apatinib; non-Hodgkin lymphoma; angiogenesis; VEGFR-2; clinical trial
Received: July 25, 2017 Accepted: November 23, 2017 Epub: January 02, 2018 Published: March 23, 2018
Background: Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. But evidence of antitumor activity in patients with lymphoma is still limited. We conducted an open-label, single-armed, exploratory study in relapse or refractory non-Hodgkin lymphoma patients for the efficacy and safety of apatinib.
Experimental design: Patients with relapse or refractory non-Hodgkin patients meet the criteria were eligible for enrollment. Treatment comprised of oral apatinib 500 mg once daily with 21 days as a treatment cycle. The primary end point was response rate. Secondary end points included progression-free survival (PFS) and overall survival (OS).
Results: Between February 2016 and December 2016, 21 patients were enrolled. The ORR (CR plus PR) was 47.6% (10 of 21 patients) included 9.5% CRs and 38.1% PRs. 23.8% patients achieved stable disease made the DCR 71.4% (15/21). The median OS was 7.3 months (95% CI, 7.1 to 7.9) and the median PFS was 7.1 months (95% CI, 4.2 to 7.3). Most patients suffered from grade 1 to grade 2 treatment-related adverse events and the most common nonhematologic adverse events were proteinuria (47.6%), hypertension (42.9%) and hand-foot syndrome (33.3%), respectively.
Conclusions: In our study, the results we presented showed apatinib might have a rapid, safe and high efficacy on relapsed or refractory non-Hodgkin lymphoma patients. Based on the data more clinic trials are expected to be taken to identification the efficacy of apatinib on lymphoma further.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.